Methamphetamine Use and MRSA Skin Infections

Results

Epidemiologic Investigation

We identified 119 case-patients with skin infections in the investigation. MRSA was isolated from 81 (68.1%) of the skin and soft tissue cultures, MSSA from 20 (16.8%), and bacteria other than S. aureus from 18 (15.1%) ( Table 1 ). Compared with controls with no skin infection, a higher percentage of patients with MRSA SSTIs were male (p<0.001). The proportion of patients that were male did not differ significantly between controls and patients with either MSSA or non-S. aureus SSTIs (p = 0.67 for MSSA, p = 0.12 for non-S. aureus) or between patients with MRSA and MSSA SSTIs (p = 0.16).

Fifteen patients who reported recently using methamphetamine were identified: 8 with MRSA SSTIs, 2 with MSSA SSTIs, and 5 controls. Half (8 [53.3%]) of the methamphetamine users were male. Ten percent of patients with MRSA skin infections (8/81) reported using methamphetamine in the past 3 months, significantly more than the 2% of controls (5/283) who reported this behavior (p<0.001). After adjusting for age, sex, and race, we determined that patients with MRSA SSTI were significantly more likely to have recently used methamphetamine than were controls (adjusted odds ratio [AOR] 5.10, 95% confidence interval [CI] 1.55-16.79) ( Table 2 ). Of the 8 methamphetamine users with MRSA SSTIs, most (5 [62.5%]) smoked or inhaled the drug. Only 1 (12.5%) injected the drug, and 1 (12.5%) took the drug orally. For 1 methamphetamine user with MRSA SSTI, we could not determine the route of drug administration. Of the 8 methamphetamine users with MRSA SSTIs in our investigation, 2 (25.0%) reported sharing drug equipment or rinse water with other persons; we did not have information on drug-sharing behavior for 1 methamphetamine user with a MRSA SSTI.

In our study population, having had a skin infection within the previous 3 months was the factor most strongly associated with current MRSA skin infection (AOR 7.92, 95% CI 4.10-15.28) ( Table 2 ). Recent sexual contact with someone with a skin infection was also a significant risk factor for MRSA skin disease (AOR 5.42, 95% CI 1.68-17.50), when compared with recent sexual contact with a person without a skin infection. Frequent skin-picking behavior was independently associated with MRSA SSTI (AOR 2.53, 95% CI 1.22-5.23). Crowded living conditions, defined as >1 person per bedroom, had a small but significant association with MRSA SSTI (AOR 1.78, 95% CI 1.004-3.15).

Only 10% of MRSA case-patients had healthcare-associated risk factors traditionally associated with MRSA infection, namely, recent hospitalization, surgery, or dialysis. Additional factors not significantly associated with MRSA SSTI in our study population included use of antimicrobial agents in the previous 6 months, recent stays in a jail or prison, bathing less than daily, history of diabetes or liver disease, recent tattoo or body piercing, and participation in contact sports in the previous 3 months. In addition, very few or no patients were HIV positive (2 [0.5%]), homeless (0), or recently had sex with someone of the same sex (7 [1.6%]), suggesting that none of these were significant risk factors for MRSA SSTI in this population.

The number of visits for S. aureus skin infections at one of the main emergency departments in our investigation increased from ≈1 per 1,000 emergency department visits to 12 per 1,000 visits over the 20 months leading up to the investigation (Figure 1). This emergency department accounted for 46.2% of all study participants in our investigation. Over the same period, MRSA infections increased from 2 to 38 per month in the same emergency department. Most emergency department S. aureus cultures for both SSTIs and non-SSTIs were resistant to methicillin, with the prevalence of methicillin-resistance remaining stable over the same 20-month period (median 82%, range 50-100%).

Figure 1.  (click image to zoom)

Number of Staphylococcus aureus skin infections at a southeastern United States emergency department, January 2004-September 2005.      

Laboratory Investigation

MRSA (n = 32) and MSSA (n = 13) isolates tested were commonly susceptible to clindamycin, daptomycin, doxycycline, gentamicin, levofloxacin, linezolid, rifampin, tetracycline, trimethoprim-sulfamethoxazole, and vancomycin ( Table 3 ). None of the MRSA isolates and only 1 (7.7%) of the MSSA isolates had inducible clindamycin resistance. MRSA susceptibility patterns of isolates from methamphetamine users and nonusers were similar, except that both MRSA isolates susceptible to erythromycin were found in those who did not use methamphetamine. The MSSA isolate from a methamphetamine user was susceptible to all but penicillin.

We detected genes for PVL in all MRSA isolates and 5 (41.7%) MSSA isolates; however, the MSSA isolate from a methamphetamine user did not carry the PVL locus. All available MRSA isolates from 6 methamphetamine users and 21 nonusers of methamphetamine had type IV SCCmec resistance complex and were PFGE type USA300. Most of the MRSA isolates were a single strain, PFGE type USA300-0114 (4 [66.7%] were methamphetamine users, 15 [71.4%] were non-methamphetamine users) (Figure 2). One third (33.3%) of MRSA isolates from methamphetamine users and one fifth (19.0%) of MRSA isolates from non-methamphetamine users were variants of USA300-0114, such as USA300-0047.

Figure 2.  (click image to zoom)

Dendrogram of pulsed-field types for methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) isolated from methamphetamine users.      

  Printer- Friendly Email ThisReferencesStevenson KB, Searle K, Stoddard GJ, Samore M. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in rural communities, western United States. Emerg Infect Dis. 2005;11:895-903.Groom AV, Wolsey DH, Naimi TS, Smith K, Johnson S, Boxrud D, et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA. 2001;286:1201-5.Naimi TS, LeDell KH, Boxrud DJ, Groom AV, Steward CD, Johnson SK, et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis. 2001;33:990-6.Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352:1436-44.McCaig LF, McDonald LC, Mandal S, Jernigan DB. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis. 2006;12:1715-23.Moran GJ, Amii RN, Abrahamian FM, Talan DA. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis. 2005;11:928-30.Levine DP, Cushing RD, Jui J, Brown WJ. Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med. 1982;97:330-8.Saravolatz LD, Markowitz N, Arking L, Pohlod D, Fisher E. Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak. Ann Intern Med. 1982;96:11-6.Cunningham JK, Liu LM. Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions. Addiction. 2003;98:1229-37.Substance Abuse and Mental Health Services Administration. Results from the 2004 National survey on drug use and health: national findings, 2005 [cited 2007 Sep 7]. Available from http://www.oas.samhsa.gov/nsduh/2k4nsduh/2k4results/2k4results.htmCenters for Disease Control and Prevention. Methamphetamine use and HIV risk behaviors among heterosexual men—preliminary results from five northern California counties, December 2001-November 2003. MMWR Morb Mortal Wkly Rep. 2006;55:273-7.Lee NE, Taylor MM, Bancroft E, Ruane PJ, Morgan M, McCoy L, et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis. 2005;40:1529-34.US Census Bureau. US Census Bureau American FactFinder, 2000 [cited 2007 Sep 7]. Available from http://www.factfinder.census.gov/home
/saff/main.html?_lang+enClinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. CLSI document M100-S16. Wayne (PA): The Institute; 2006.Jorgensen JH, Crawford SA, McElmeel ML, Fiebelkorn KR. Detection of inducible clindamycin resistance of staphylococci in conjunction with performance of automated broth susceptibility testing. J Clin Microbiol. 2004;42:1800-2.Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant Staphylococcus aureus infections among emergency department patients in 11 U.S. cities. N Engl J Med. 2006;355:666-74.Maslow J, Slutsky A, Arbeit R. Application of pulsed-field gel electrophoresis to molecular epidemiology. In: Persing D, Smith T, Tenover F, White T, editors. Diagnostic molecular microbiology: principles and applications. Washington: American Society for Microbiology; 1993. p. 563-72.McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol. 2003;41:5113-20.Kazakova SV, Hageman JC, Matava M, Srinivasan A, Phelan L, Garfinkel B, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med. 2005;352:468-75.Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus infections in correctional facilities-Georgia, California, and Texas, 2001-2003. MMWR Morb Mortal Wkly Rep. 2003;52:992-6.Campbell KM, Vaughn AF, Russell KL, Smith B, Jimenez DL, Barrozo CP, et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus infections in an outbreak of disease among military trainees in San Diego, California, in 2002. J Clin Microbiol. 2004;42:4050-3.Young DM, Harris HW, Charlebois ED, Chambers H, Campbell A, Perdreau-Remington F, et al. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Arch Surg. 2004;139:947-51.Molitor F, Truax SR, Ruiz JD, Sun RK. Association of methamphetamine use during sex with risky sexual behaviors and HIV infection among non-injection drug users. West J Med. 1998;168:93-7.Hirshfield S, Remien RH, Walavalkar I, Chiasson MA. Crystal methamphetamine use predicts incident STD infection among men who have sex with men recruited online: a nested case-control study. J Med Internet Res. 2004;6:e41.Cook HA, Furuya EY, Larson E, Vasquez G, Lowy FD. Heterosexual transmission of community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007;44:410-3.Gordon RJ, Lowy FD. Bacterial infections in drug users. N Engl J Med. 2005;353:1945-54.Vogt TM, Perz JF, Van Houten CK Jr, Harrington R, Hansuld T, Bialek SR, et al. An outbreak of hepatitis B virus infection among methamphetamine injectors: the role of sharing injection drug equipment. Addiction. 2006;101:726-30.Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer AS, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005;352:1445-53.Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus infections among competitive sports participants—Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep. 2003;52:793-5.Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA; Participants in the Centers for Disease Control and Prevention-Convened Experts' Meeting on Management of MRSA in the Community. Strategies for clinical management of MRSA in the community: summary of an experts' meeting convened by the Centers for Disease Control and Prevention, 2006 [cited 2007 Sep 7]. Available from http://www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf

Emerg Infect Dis.  2007;13(11):1707-1713.  ©2007 Centers for Disease Control and Prevention (CDC)
This is a part of article Methamphetamine Use and MRSA Skin Infections Taken from "Erectile Disfunction Drugs" Information Blog

Diabetic Neuropathy: An Intensive Review

Jeremiah John Duby; R. Keith Campbell; Stephen M. Setter; John Raymond White; Kristin A. Rasmussen

Abstract and Introduction

Abstract

Purpose: The epidemiology, classification, pathology, and treatment of diabetic neuropathy are reviewed.
Summary: Diabetic peripheral neuropathy is a common complication of diabetes that can cause significant morbidity and mortality. Some 30% of hospitalized and 20% of community-dwelling diabetes patients have peripheral neuropathy; the annual incidence rate is approximately 2%. The primary risk factor is hyperglycemia. Sensorimotor neuropathy is marked by pain, paresthesia, and sensory loss. Cardiac autonomic neuropathy (CAN) may contribute to myocardial infarction, malignant arrhythmia, and sudden death. Gastroparesis is the most debilitating complication of gastrointestinal autonomic neuropathy. Genitourinary autonomic neuropathy can cause sexual dysfunction and neurogenic bladder. The pathology of diabetic neuropathy involves oxidative stress, advanced glycation end products, polyol pathway flux, and protein kinase C activation; all contribute to microvascular disease and nerve dysfunction. For symptom management current evidence from clinical trials supports the use of desipramine, amitriptyline, capsaicin, tramadol, gabapentin, bupropion, and venlafaxine as preferred medications. Citalopram, nonsteroidal antiinflammatory drugs, and opioid analgesics may be used as adjuvant agents. Lamotrigine, oxcarbazepine, paroxetine, levodopa, and α-lipoic acid are alternative considerations. Evidence supporting the use of zonisamide, fluoxetine, mexiletine, dextromethorphan, and phenytoin is considered equivocal. Complementary therapies have also shown efficacy. The symptoms of CAN may be ameliorated with fludrocortisone, clonidine, midodrine, dihydroergotamine or caffeine, octreotide, and β-blockers. Gastroparesis may be treated with metoclopramide or erythromycin. The most promising disease-modifying therapy is ruboxistaurin, which is in Phase III trials. Glycemic control remains the foundation of prevention and the prerequisite of adequate treatment.
Conclusion: Diabetic neuropathy is a many-faceted complication of diabetes that can be managed symptomatically with an array of drugs.Introduction

Diabetic peripheral neuropathy is a common complication of diabetes that can affect virtually every tissue of the body and cause significant morbidity and mortality. Current understanding of the pathophysiology is complicated and incomplete, but basic experimental research is on the threshold of producing the first disease-modifying therapies. The available treatments are modestly to moderately effective in relieving symptoms but are limited by adverse effects and drug interactions. The emphasis of management of diabetic neuropathy remains prevention by glycemic control. The purpose of this article is to review the epidemiology, classification, pathology, and treatment of diabetic neuropathy.

Section 1 of 6 Jeremiah John Duby, Pharm.D., is General Practice Resident, University of Arizona, Tucson. R. Keith Campbell, B.Pharm., M.B.A., CDE, FASHP, FAPhA, is Professor; Stephen M. Setter, Pharm.D., D.V.M., is Assistant Professor; and John Raymond White is Associate Professor of Pharmacotherapy, Department of Pharmacotherapy, College of Pharmacy, Washington State University (WSU), Spokane. Kristin A. Rasmussen is a D.V.M. degree candidate, College of Veterinary Medicine, WSU.
Am J Health-Syst Pharm 61(2):160-176, 2004. © 2004 American Society of Health-System Pharmacists
This is a part of article Diabetic Neuropathy: An Intensive Review Taken from "Erectile Disfunction Drugs" Information Blog

Pfizer Celebrates Sixth Anniversary of Viagra(reg) by Unveiling New Patient Savings Program

NEW YORK — In celebration of the sixth anniversary of the launch of Viagra(reg) (sildenafil citrate), Pfizer Inc today announced the launch of an innovative new savings program called The Value Card for Viagra. The new program offers men a convenient way to get a free Viagra prescription every time they fill six eligible prescriptions.

"This unique savings program gives the more than 30 million men with erectile dysfunction, or ED, a new reason to talk to their physicians about sexual health," said Steven Lamm, MD, Clinical Assistant Professor of Medicine, New York University.

Enrolling in The Value Card for Viagra Program

To maximize the options men have when deciding where to fill their prescriptions, The Value Card for Viagra program will be offered at more than 33,000 retail pharmacies, including Eckerd(reg), Rite-Aid(reg), Kroger(reg), K-Mart(reg), Duane Reade(reg), Costco(reg), Medicine Shoppe(reg) Pharmacies, Target(reg), Long's(reg), Giant Food(reg) (PA), Giant Food(reg) (MD), Stop & Shop(reg), Bi-Lo(reg), Brunos(reg), Tops Markets(reg), Happy Harry's(reg), Giant Eagle(reg), Brooks(reg) and other participating chain and independent pharmacies. Enrollment information and temporary cards are currently available at these pharmacies; this information will also be available at thousands of physicians' offices across the country.

A patient can use the temporary card to fill his first prescription and then must officially enroll in The Value Card for Viagra program by calling 1-800-578-1688. Enrollment is also offered at Viagra.com. Pharmacists can obtain program and enrollment information by calling 1-800-522-7487. The program may not be offered in some areas or at some pharmacies.

Once enrolled in the program, participants receive The Value Card for Viagra, which should then be presented each time they fill or refill a qualifying Viagra(reg) (sildenafil citrate) prescription. After the sixth prescription is filled, the seventh can be filled free of charge. Men who pay for their entire prescription or part of their prescription not covered by insurance are eligible for the program. Pills obtained with a co-payment will not count for this program, nor will pills obtained via Medicare-endorsed discount programs, or via Pfizer patient assistance programs such as the Pfizer Share Card(reg), Connection to Care(reg), or Sharing the Care(reg).

"Viagra, the most-prescribed ED treatment, has six years of proven safety and efficacy," said Sharlea Leatherwood, Pharm. D., independent pharmacy owner. "The Value Card for Viagra makes it possible for more men to take advantage of this breakthrough treatment, enabling them to easily and quickly enroll at participating pharmacies and doctors' offices across the country, as well as online or by telephone."

The Number One Prescribed Oral ED Treatment

Since its introduction in 1998, 23 million men have been prescribed Viagra(reg) (sildenafil citrate) for ED. Furthermore, in a long-term, open-label clinical trial, 96% of men reported satisfaction with Viagra, which is covered by most health plans.

"Six years ago, Viagra initiated the dialogue about men's sexual health, including erection problems-an important and still under-treated health problem experienced to some degree by an estimated 30 million men," said Janice Lipsky, U.S. Team Leader, Viagra. "Today, physicians put their trust in Viagra as an ED medication that affords men performance when they need it. There's no other tablet proven to work better or faster to treat ED."

About Viagra

Viagra is a prescription medication indicated for the treatment of ED. Viagra is available only from health care providers and should always be used in accordance with its approved labeling. Viagra is contraindicated in patients who use nitrates in any form at any time.

Patients should discuss their general health status with their doctors to ensure that they are healthy enough to engage in sexual activity. If patients experience pain, nausea, or any other discomfort during sex, or an erection that lasts longer than four hours, they should seek medical help.

The most common side effects of Viagra(reg) (sildenafil citrate) are headache, facial flushing and upset stomach. Less commonly, bluish vision, blurred vision or sensitivity to light may briefly occur.

Patients with recent serious cardiovascular events, hypertension or controlled hypertension or retinitis pigmentosa did not participate in pre-approval clinical trials. In these patients, physicians should prescribe Viagra with caution. The use of Viagra offers no protection against sexually transmitted diseases, including human immunodeficiency virus (HIV).

Discovered and developed by Pfizer, Viagra is the breakthrough oral treatment for erectile dysfunction that is found to be effective and well tolerated in more than 130 completed and ongoing clinical studies. Viagra has been approved by regulatory authorities in more than 123 countries around the world and is among the most widely prescribed medications, with more than 130 million prescriptions written for 23 million men worldwide.

Pfizer Inc discovers, develops, manufactures and markets leading prescription medications for humans and animals and many of the world's best-known consumer products.

www.viagra.com
This is a part of article Pfizer Celebrates Sixth Anniversary of Viagra(reg) by Unveiling New Patient Savings Program Taken from "Erectile Disfunction Drugs" Information Blog

From The $800 Million Pill - Me Too

In This ArticleChapter 8: Me Too!Section 1Section 2Section 3Section 4Section 5Section 6Section 7Section 8Section 9Section 10Section 11ReferencesRelated Links

Section 8

The Prilosec-to-Nexium transition exemplified a common industry practice. Throughout the 1990s, the drug industry poured billions of research dollars into developing alternatives to drugs that were approaching the end of their patent terms. In most cases, the alternatives were little changed from the originals. The better the original sold, the more likely it was that the company would devote considerable research resources to generating a copycat version with renewed patent life.

Another example that garnered considerable public attention was Schering-Plough's Claritin, one of the antiallergy medicines developed in the early 1980s as a nonsedating alternative to an earlier generation of antihistamines. By the late 1990s, the drug was generating over $2 billion a year in sales for Schering-Plough, a figure that was growing rapidly because of the 1997 legalization of direct-to-consumer advertising. To reach the estimated thirty-five million allergy sufferers in the United States, Schering-Plough poured hundreds of millions of dollars a year into ads for the drug. Consumers were encouraged to ask their doctors for a pricey prescription–it cost eighty dollars for a month's supply–that, according to the original studies submitted to the FDA, worked only marginally better than a placebo.

Though you would never know it from the television advertisements featuring handsome women frolicking through flowering fields oblivious to the pollen-laden air, the FDA's reviewer was openly skeptical about the drug's efficacy at the low dose offered by Schering-Plough. The company, which tested the drug on thousands of patients, needed a low dose to ensure that it would be nonsedating, which was the only way the new drug would be able to gain a toehold in the already crowded antihistamine market. But at the low, nonsedating dose, clinical trials showed that only 43 to 46 percent of Claritin users gained relief of allergy symptoms compared to a third of patients on a sugar pill. A separate study that asked doctors to assess the patients on the placebo found that 37 to 47 percent of them had a "good to excellent response to treatment," which as a practical matter was no different than those who took the real pill.[19] In addition to questioning its marginal medical significance, other reviewers at that late 1980s FDA hearing worried that Claritin, whose generic name is loratadine, might be a carcinogen. It took the company several more years of studies before it could dispel those fears. Finally, in 1993, the drug was approved. The delays actually proved to be an auspicious event for Schering-Plough. In the early 1990s, patients on Seldane and Hismanal, the first nonsedating antihistamines to hit the market, began turning up in hospital emergency rooms because of the drugs' violent interactions with other drugs and the development of life-threatening heart irregularities. By the time Claritin hit pharmacists' shelves, there was pent-up demand for a safe alternative, and the new drug immediately jumped to number one in sales in its class.

Yet in the late 1990s, as Claritin neared the end of its patent term, Schering-Plough launched a massive lobbying campaign in Washington to get an extension on its patent. The company claimed the long delays at the FDA had robbed it of years of market exclusivity. Aware of the history, Congress rebuffed Schering-Plough's frequent requests.

Forced to fall back on research and development, Schering-Plough scientists took apart loratadine to see what made it tick. They discovered the active part of the drug was actually a metabolite of the whole molecule, which became active in the stomach after patients began digesting the pill. They patented this metabolite, called it desloratadine, and filed a new drug application with the FDA. It was approved in late 2001, just months before the expiration of loratadine's patent. The company launched a massive advertising campaign that convinced millions of their customers to switch to the new, equally expensive but no more effective drug. Then, to frustrate the generic companies getting ready to sell loratadine, Schering-Plough announced it would begin selling Claritin as an over-the-counter allergy remedy.[20] Public-sector science has sometimes pushed industry researchers down the road to better medicine, only to discover as they neared the end of their labors that they developed yet another me-too drug. During the late 1990s, few drug classes received more media attention than a new pain reliever known within the medical community as Cox-2 inhibitors. The original members of this new drug class were Celebrex, made by G.D. Searle (later bought by Pharmacia), and Vioxx, made by Merck. In 2001, Pharmacia came out with a follow-up drug to Celebrex called Bextra.Previous PageSection 9 of 12Next Page: Section 9
Medscape General Medicine.  2004;6(2):57.  ©2004 Medscape


This is a part of article From The $800 Million Pill - Me Too Taken from "Discount Allegra Fexofenadine" Information Blog

Pearls for Grooming.

As with other antidepressants, concomitant use of fluoxetine products may lawsuit significant increases in pimozide serum levels. Because of pimozide's narrow therapeutic forefinger and known risk for prolongation of the QT measure, coadministration of these 2 drugs is contraindicated.As with other thiazolidinediones, rosiglitazone is associated with a risk for written material belongings that may exacerbate or lead to pith skip. Rosiglitazone plus metformin tablets should therefore not be used in patients with NYHA solicitation 3 and 4 cardiac province. All patients should be observed for signs and symptoms of action card event, and therapy should be discontinued if any change of state in cardiac status occurs.Sudden demise has been reported in children with structural cardiac abnormalities receiving normal-dose therapy with CNS stimulants. Although some structural cardiac abnormalities are linked to an fencesitter risk for sudden Putting to death, use of dexmethylphenidate and other stimulants in children, adolescents, or adults with these defects is not recommended. Legal Rejection The artifact presented here does not necessarily reflect the views of Medscape or companies that aid educational scheduling on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Term of office and off-label uses of approved products. A qualified healthcare grownup should be consulted before using any therapeutic chemical means discussed. Readers should verify all profits and data before treating patients or employing any therapies described in this educational act.
This is a part of article Pearls for Grooming. Taken from "Prozac Fluoxetine Generic" Information Blog

FDA Safety Changes: Sarafem/Prozac, Avandamet, Focalin XR.

This proceedings is part of an ongoing CME/CE initiative to provide grouping on kind changes reported by the FDA.
Activities of this level will be posted on Medscape on a weekly dry land.
July 19, 2007
This is a part of article FDA Safety Changes: Sarafem/Prozac, Avandamet, Focalin XR. Taken from "Prozac Fluoxetine Generic" Information Blog

Vardenafil Improves Erectile Function in Depressed Men.

NEW YORK (Reuters Health) Feb 10 - Vardenafil improves erectile mathematical software system and Psychological state in men with both disorders, according to a subject in the January Habitant Ledger of Psychiatry.
Although economic malady is common among men with erectile dysfunction, the authors explain, previous studies have not investigated the capability mental financial aid benefits of phosphodiesterase inhibitor therapy in men with erectile dysfunction.
Vardenafil online
- dr.
Raymond Rosen from UMDNJ-Robert Wood Presiding officer Lyndon Dr. Johnson Medical Structure, Piscataway, New Knit and colleagues evaluated the efficacy of vardenafil in the manner of 280 men with erectile dysfunction and clinically diagnosed but untreated mild John Roy Student depressive physiological country.
The subjects were assigned to vardenafil or therapy for 12 weeks.
All erectile subprogram parameters improved significantly with vardenafil management, the authors estimation card.
Vardenafil social control was associated with significant improvements in sexual sexual relation purport, orgasmic single-valued subprogram, coverall wear, and sexual touch sensation, the results indicate.
This is a part of article Vardenafil Improves Erectile Function in Depressed Men. Taken from "Prozac Fluoxetine Generic" Information Blog